tetano
Editor, Senior Moderator
Pediatr Int. 2014 Oct 20. doi: 10.1111/ped.12526. [Epub ahead of print]
Impact of time-to-treatment of Oseltamivir on influenza hospitalization costs among Korean children.
Lim JK1, Kilgore PE, Aiello AE, Foxman B, Letson GW, Jang GY, Chung E, Song YH, Kim YK.
Author information
Abstract
BACKGROUND:
While oseltamivir is a common influenza treatment, there is a lack of data about the economic benefits of timely oseltamivir treatment.
METHODS:
From February 2004 through June 2007, 116 hospitalized children ≤15 years-of-age with laboratory-confirmed influenza who received oseltamivir treatment were identified through a retrospective medical chart review. Demographic, clinical, and cost data were abstracted and multivariable linear regression was used to assess the association between oseltamivir time-to-treatment and treatment-related cost among hospitalized children with laboratory-confirmed influenza.
RESULTS:
Overall, 28 per cent (n=33) of patients were treated with oseltamivir ≥ day-3 following admission. Influenza rapid diagnostics were used in a significantly lower proportion of patients treated with oseltamivir ≥ day-3 of admission compared to those whose oseltamivir therapy started earlier. Multivariable linear regression showed that children who received oseltamivir 3+ days after admission were associated with a 60.84% ([95% CI, 32.59 - 95.11]) increase in treatment-related hospital charges, compared to those treated with oseltamivir on admission.
CONCLUSION:
Delayed onset of oseltamivir was found to be associated with increased treatment-related hospital charges among children hospitalized with laboratory-confirmed influenza.
This article is protected by copyright. All rights reserved.
KEYWORDS:
Influenza; children; hospital charges; influenza rapid diagnostic tests; oseltamivir
PMID:
25330041
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25330041
Impact of time-to-treatment of Oseltamivir on influenza hospitalization costs among Korean children.
Lim JK1, Kilgore PE, Aiello AE, Foxman B, Letson GW, Jang GY, Chung E, Song YH, Kim YK.
Author information
Abstract
BACKGROUND:
While oseltamivir is a common influenza treatment, there is a lack of data about the economic benefits of timely oseltamivir treatment.
METHODS:
From February 2004 through June 2007, 116 hospitalized children ≤15 years-of-age with laboratory-confirmed influenza who received oseltamivir treatment were identified through a retrospective medical chart review. Demographic, clinical, and cost data were abstracted and multivariable linear regression was used to assess the association between oseltamivir time-to-treatment and treatment-related cost among hospitalized children with laboratory-confirmed influenza.
RESULTS:
Overall, 28 per cent (n=33) of patients were treated with oseltamivir ≥ day-3 following admission. Influenza rapid diagnostics were used in a significantly lower proportion of patients treated with oseltamivir ≥ day-3 of admission compared to those whose oseltamivir therapy started earlier. Multivariable linear regression showed that children who received oseltamivir 3+ days after admission were associated with a 60.84% ([95% CI, 32.59 - 95.11]) increase in treatment-related hospital charges, compared to those treated with oseltamivir on admission.
CONCLUSION:
Delayed onset of oseltamivir was found to be associated with increased treatment-related hospital charges among children hospitalized with laboratory-confirmed influenza.
This article is protected by copyright. All rights reserved.
KEYWORDS:
Influenza; children; hospital charges; influenza rapid diagnostic tests; oseltamivir
PMID:
25330041
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25330041